Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Breaking The Pain Market’s Addiction To Opioids

Executive Summary

The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.

You may also be interested in...



Latigo Raises $135m To Channel Vertex

The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.

Vertex’s VX-548 For Acute Pain May Be Right On Time For Market

The company’s NaV1.8 inhibitor succeeded in Phase III acute pain trials and will be submitted for US FDA approval in mid-2024. It may reach the market in time for Medicare reimbursement changes favoring non-opioids.

Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel